Search results
COVID-flu combo vaccine shows ‘positive’ results in phase 3 trials, Moderna says: A 'two-for' option
Fox News· 7 days agoA combination COVID-influenza vaccine is apparently one step closer to hitting the market. Moderna,...
FDA modifies strain recommendation for fall COVID vaccine amid variant shifts, uptick in cases
Center for Infectious Disease Research and Policy· 3 days agoOn June 5, the FDA's vaccine advisory group recommended a switch to the JN.1 variant, though it held...
2-in-1 shot for flu and COVID shows promise in advanced trial
Live Science via Yahoo News· 7 days agoModerna representatives told news outlets that the company aspires to have the new shot approved by...
Analysis | Court rejects abortion pill challenge, but what happens next?
Washington Post· 3 days agoWhat do you think is next in the fight over medication abortion? Today’s edition: Senate Republicans...
Factbox-Layoffs pile up in US, Canada as companies uncertain of economy
MSN News· 4 days ago(Reuters) -Companies in the U.S. and Canada have continued their job cuts in 2024 after letting go...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 5 days agoThough it has a booster Covid shot, like rivals Moderna and Novavax, analysts don't expect sales to...
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day...
Benzinga· 3 days agoShares of AMMO, Inc. POWW fell sharply during Friday's session following fourth-quarter results....
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 5 days agoThe company noted that it achieved 48% market share for Covid vaccines in the U.S. during the fall...
National Academies Issue New Broad Definition of Long COVID
Medscape· 7 days agoA new broadly inclusive definition of long COVID from the National Academies of Sciences,...
Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing
BioPharma Dive via Yahoo Finance· 3 days agoThe Japanese pharma paid $100 million to secure option rights to an Ascentage drug. Elsewhere, J.P....